Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-medicine-collaborates-with-south-korean-institutes-to-develop-an-ai-powered-analytic-tool-for-lung-cancer-immunotherapy
https://www.med.cuhk.edu.hk/press-releases/cuhk-medicine-collaborates-with-south-korean-institutes-to-develop-an-ai-powered-analytic-tool-for-lung-cancer-immunotherapy

CU Medicine collaborates with South Korean institutes to develop an AI-powered analytic tool for lung cancer immunotherapy

Professor Tony MOK Shu Kam from The Chinese University of Hong Kong’s (CUHK) Faculty of Medicine (CU Medicine) has collaborated with South Korea’s Seoul National University College of Medicine, Sungkyunkwan University School of Medicine, Ajou University School of Medicine and AI startup Lunit to develop an AI-powered analytic tool to predict the effectiveness of a complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer (NSCLC).

 

The tool conducts a spatial analysis of the distribution of tumour infiltrating lymphocytes biomarkers in whole slide images which can predict treatment outcomes with immune checkpoint inhibitors, the current first-line therapy for advanced NSCLC. Study results showed that the AI-powered analysis of tumour infiltrating lymphocytes correlates with tumour response and progression-free survival, meaning it may help optimise treatment selection in clinical practice. These findings were recently published in the Journal of Clinical Oncology.

 

Immune checkpoint inhibitors are standard therapy for advanced NSCLC with PD-L1 expression

 

Lung cancer is one of the most common cancers in the world, accounting for 1.8 million deaths every year. According to the Hong Kong cancer registry, lung cancer is the leading cause of cancer deaths and the most common cancer in the city, with more than 5,000 new cases every year. NSCLC accounts for above 80% of all lung cancers.

 

Immune checkpoint inhibitors are a standard first-line therapy for advanced NSCLC with PD-L1 expression, known as anti PD-1 checkpoint inhibitors. When protein PD-1 on immune cell T-cell binds with ligand PD-L1 from cancer cells, it prevents the immune system from killing cancer cells. The inhibitors serve the purpose of preventing the binding from taking place and allowing the immune system to do its work and kill cancer cells.

 

Prof. Tony Mok

Professor Tony Mok

Professor Tony Mok, Li Shu Fan Professor of Clinical Oncology and Chairman of the Department of Clinical Oncology at CU Medicine said, “The outcome of anti PD-1 checkpoint inhibitors may vary depending on the patient’s tumour microenvironment but there is currently no standard biomarker addressing this. Tumour infiltrating lymphocytes, in theory, are the main activator of antitumour immunity which could be a promising biomarker for predicting treatment outcomes with immune checkpoint inhibitors. But the current quantification method is labour-intensive and relies on spatial distribution in whole-slide images, limiting utility and objectivity.”

Immune phenotypes correlating with tumour response to immune checkpoint inhibitors

 

The AI-powered spatial tumour infiltrating lymphocytes analyser developed by the collaborative research team is capable of segmentation and quantification of multiple histologic components from whole-slide images, including cancer epithelium, cancer stroma and tumour infiltrating lymphocytes. Then, through deep learning-based AI model training, three immune phenotypes: inflamed, immune-excluded and immune-desert are generated. (Please refer to table 1 for the definition of the three immune phenotypes)

 

Results showed that the inflamed immune phenotype correlates with enrichment in local immune cytolytic activity, a higher response rate, and prolonged progression-free survival compared with patients with the other two phenotypes. (Please refer to table 2 for full data)

 

Professor Mok added, “This is the first study on AI-powered automated tumour infiltrating lymphocytes analysis in advanced NSCLC. In this study, we have proved that the AI-powered spatial tumour infiltrating lymphocytes analyser is capable of predicting clinical outcomes of immune checkpoint inhibitors in patients with NSCLC. This may serve as a complementary biomarker to tumour proportion score, the current PD-L1 measurement.”

 

Table 1: The definition of the three immune phenotypes:

Immune phenotypes

Tumour infiltrating lymphocytes density in cancer epithelium

Tumour infiltrating lymphocytes density in cancer stroma area

Inflamed

Above threshold (> 106/ mm²)

Above threshold (> 357/ mm²)

Immune-excluded

Below threshold (< 106/ mm²)

Above threshold (> 357/ mm²)

Immune-desert

Below threshold (< 106/ mm²)

Below threshold (< 357/ mm²)

Table 2: An overview of the median progression-free survival and overall survival projected by the AI-powered analyser over the three immune phenotypes:

Immune phenotypes

Median progression-free survival

Overall survival

Inflamed

4.1 months

24.8 months

Immune-excluded

2.2. months

14.0 months

Immune-desert

2.4 months

10.6 months

More Press Releases

CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

Research
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

Research
Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Symposium
CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

Surgical advancement
CUHK-HKU-UCL study unravels how gene mutation leads to congenital megacolon providing clues for the development of novel therapeutic strategies

CUHK-HKU-UCL study unravels how gene mutation leads to congenital megacolon providing clues for the development of novel therapeutic strategies

Research
CUHK-Baylor Study Proves Aspirin Reduces the Risk of Preeclampsia by Decelerating the Metabolic Clock of Gestation

CUHK-Baylor Study Proves Aspirin Reduces the Risk of Preeclampsia by Decelerating the Metabolic Clock of Gestation

Research
CUHK and International Experts in Diabetes Care Joined Hands for Four Years Developing a Multicomponent, Integrated Strategy for Diabetes under The Lancet

CUHK and International Experts in Diabetes Care Joined Hands for Four Years Developing a Multicomponent, Integrated Strategy for Diabetes under The Lancet

International collaboration
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
Inaugural Collaboration between CUHK and AstraZeneca on Diabetic Kidney Disease Research Advancing a Global Strategy Against Diabetic Kidney Disease

Inaugural Collaboration between CUHK and AstraZeneca on Diabetic Kidney Disease Research Advancing a Global Strategy Against Diabetic Kidney Disease

International collaboration
Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Response
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
Two CUHK Research Projects Receive State Science and Technology Awards

Two CUHK Research Projects Receive State Science and Technology Awards

Awards and honors
The Chinese University of Hong Kong and Imperial College Collaborate on Healthcare Innovation and Biomedical Robotics

The Chinese University of Hong Kong and Imperial College Collaborate on Healthcare Innovation and Biomedical Robotics

International collaboration
CUHK and US Experts Collaborate to Provide Clinical Genetic Training to Set up The Territory's First One-Stop Outpatient Genetic Clinic

CUHK and US Experts Collaborate to Provide Clinical Genetic Training to Set up The Territory's First One-Stop Outpatient Genetic Clinic

International collaboration
CUHK Successfully Performed Hong Kong's First Robotic Endoscopic Scarless Surgery - A Major Endoscopic Technological Breakthrough

CUHK Successfully Performed Hong Kong's First Robotic Endoscopic Scarless Surgery - A Major Endoscopic Technological Breakthrough

Surgical advancement

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.